The Infectious Disease Alliance (ID Alliance) will host a hybrid event titled “Bridging Science, Advocacy, and Practice: A Unified Approach to Combating Antimicrobial Resistance,” taking place in Statens Serum Institut (SSI) Campus, Copenhagen, Denmark, and online via Teams. This event will bring together global experts, policymakers, researchers, and advocates to explore collaborative approaches for addressing antimicrobial resistance (AMR) as a growing global challenge that cuts across human health, animal health, agriculture, and the environment.
Search
Tackling AMR with Outcomes-Based Financing: Findings from Tanzania and Senegal
On February 25, Neha Agarwal, senior director of strategy at PATH and Alliance board vice chair, led a session for Stanford Mussallem Center for Biodesign’s Innovation and Health Equity Series. She discussed how outcomes-based financing (OBF) can be leveraged to tackle antimicrobial resistance (AMR). Her talk, which provided a first look at data from a year-long study in Tanzania and Senegal, emphasized how innovative financing mechanisms could reshape global health strategies.
Outcomes-Based Finance as a Tool for Health Equity and Innovation
Hybrid, Member Events, Virtual
Join Stanford Mussallem Center for Biodesign on February 25 for the next session in their Innovation and Health Equity Discussion Series where Neha Agarwal, senior director of strategy at PATH and Alliance board vice chair, will discuss an innovative outcomes-based financing (OBF) mechanism being developed in partnership with the governments of Tanzania and Senegal, the Bay Area Global Health Alliance, and Pfizer to reinforce antimicrobial stewardship efforts in LMICs.
PATH, Pfizer, and the Bay Area Global Health Alliance Partner to Combat Antimicrobial Resistance in Senegal and Tanzania Using an Outcomes-Based Financing Mechanism
During the Clinton Global Initiative (CGI) 2024 Annual Meeting, PATH, in partnership with the Bay Area Global Health Alliance and Pfizer, announced a Commitment to Action: Outcomes-Based Financing as a Tool to Curb AMR in LMICs. This commitment aims to combat antimicrobial resistance (AMR) and incentivize antimicrobial stewardship (AMS) through an innovative outcomes-based financing mechanism.
AMR takes center stage at UN assembly
GHTC Read More
Essentials for epidemic preparedness and response
PATH Read More
Call to action: Advancing global cooperation, R&D, and equity to address AMR
GHTC Read More
UNGA79
The 79th session of the UN General Assembly (UNGA 79) will open on Tuesday, 10 September 2024. The first day of the high-level General Debate will be Tuesday, 24 September 2024. When global leaders meet at the UN, they will confront yet another year of complex crises and conflicts — as a deeply divided world watches. The UN is the only place on Earth where countries — whether big or small — have a say. The debates and conversations that will unfold during UNGA 79 will shape the solutions that can redefine our future. UNGA 79 will also include High-level Meetings on two issues of existential importance: Antimicrobial resistance (AMR) and the global threat of sea-level rise.
The Trinity Challenge on Antimicrobial Resistance – eight finalists selected for up to £1 million prize
Living Goods, Pendulum Read More
GHTC provides recommendations for World Health Assembly at HHS stakeholder listening session
GHTC Read More
UC Davis: Rx One Health Field Institute
Novel pathogens, climate change, biodiversity loss, food insecurity, health disparities, antimicrobial resistance, water scarcity, pollution… our planet faces a host of interrelated serious challenges in the Anthropocene era. The Rx One Health Field Institute at Alliance member UC Davis is a transformative field-based experiential learning course focused on One Health core competencies for graduate students and early career professionals from all disciplines.
The Race Against Resistance: Global Perspectives on Tackling AMR
Join Cepheid for their Race Against Resistance: Global Perspectives on Tackling AMR webinar, which will share cross-regional expertise, including real-world lived experience of managing outbreaks, meta-analysis and novel diagnostic approaches in the fight against antimicrobial resistance and threat to last-line antibiotics.